| 產(chǎn)品名稱 |
pRRB20IF-23 [SCC2128] |
| 商品貨號 |
B240506 |
| Designations |
pRRB20IF-23 [SCC2128] |
| Species |
Homo sapiens, human |
| Depositors |
Schering Corp. |
| Applications |
produces protein interferon, type 1, cluster interferon alpha gene family (leukocyte), interferon, alpha (leukocyte), interferon, type 1, cluster |
| Insert |
DNA: cDNA Insert lengths(kb): 1.899999976158142 Gene product: interferon, alpha 2 [IFNA2] Target Gene: interferon, type 1, cluster |
| Insert Size (kb) |
1.900 |
| Media |
ATCC® Medium 1227: LB Medium (ATCC medium 1065) with 50 mcg/ml ampicillin
|
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Shipping Information |
Distributed: freeze-dried |
| Comments |
Restriction digests of the clone give the following sizes (kb): EcoRI--7.2; EcoRI/BamHI--4.3, 3.0; EcoRI/PstI--5.9, 1.4; BglII--7.0, 0.2; EcoRI/BglII--4.0, 3.1, 0.2. Expresses IFNA2 using the encoded T7 RNA polymerase. The plasmid consists of the following elements with their directions of transcription: T7 gene 10 promoter > - IFNA2 > - < T7 gene 1.1 promoter - < T7 gene 1D - < lac po - < pMB1 ori - < ampR. |
| References |
Reim RL, et al. Expression systems utilizing bacteriophage T7 promoters, gene sequences, and T7 RNA polymerase. US Patent 5,122,457 dated Jun 16 1992
|
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
